Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911625 · ClinicalTrials.gov registry record · Phase 4
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
A Phase 4 study of Type 2 Diabetes and Renal Insufficiency, sponsored by Loyola University.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 3
- Study locations
NCT00911625: Completed Phase 4 study of Type 2 Diabetes and Renal Insufficiency, sponsored by Loyola University.
NCT00911625 is a Phase 4 study of Type 2 Diabetes and Renal Insufficiency that has completed, run by Loyola University. The registered enrollment target is 114 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00911625, a Phase 4 study of Type 2 Diabetes and Renal Insufficiency, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 3
- Study locations
Study Summary
It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: \< 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.
Primary Outcome
Participants have their blood glucose measured daily for six days. The average blood glucose measure over all six days is compared between the two treatment cohorts.
Conditions Studied
Interventions
- DRUG 0.5 units/kg daily insulin
- DRUG 0.25 units/kg daily insulin
Study Locations (3)
Illinois
- Northwestern University Medical Center - Chicago
- Rush University Medical Center - Chicago
- Loyola University Hospital - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2009-01-21 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 4 |
What the finished NCT00911625 record still lists
NCT00911625 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which 0.5 units/kg daily insulin is the first listed.
NCT00911625 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00911625 about?
NCT00911625 is a clinical study titled "Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency". It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisi...
What is the current status of trial NCT00911625?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2009-01-21. Estimated completion is 2011-06-30.
What conditions does trial NCT00911625 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Renal Insufficiency.
What interventions are being tested in trial NCT00911625?
The interventions under investigation include: 0.5 units/kg daily insulin (DRUG), 0.25 units/kg daily insulin (DRUG).
Who is sponsoring clinical trial NCT00911625?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00911625 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00911625's enrollment target sits among peer trials
114 141st of 327 higher than 187 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI